DBV Technologies S.A. (DBV.F)
Frankfurt · EUR · Healthcare · Biotechnology
€1.74 (-0.12%) as of
Key statistics
- Market cap
- 545.52M
- EPS (TTM)
- -0.6200
- Dividend yield
- 0.00%
- 52-week range
- 1.5010 – 4.7500
- Beta
- -0.24
- Revenue (TTM)
- 5.04M
- Profit margin
- 0.00%
- Volume
- 3.86k
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Châtillon, France
- Employees
- 170
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.